iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aurobindo Pharma's Subsidiary Secures License Deal for Leukemia Drug, Stock Surges by 2%

23 Jun 2023 , 02:29 PM

Aurobindo Pharma’s share price experienced a 2.5 % increase on June 23 as one of its subsidiaries entered into a sub-licensing agreement with the Medicines Patent Pool for Nilotinib Capsules.

Aurobindo Pharma’s wholly owned subsidiary, Eugia Pharma Specialities Limited (Eugia), has signed a voluntary sub-licensing agreement with the Medicines Patent Pool (MPP). The agreement aims to develop and market Nilotinib capsules, originally developed by Novartis, for the treatment of chronic myeloid leukemia in 44 low and middle-income countries.

This includes seven countries where patents for the drug are either pending or already in force. The production of the product will take place at Eugia Pharma’s facility located in Medchal, Malkajgiri district, Telangana.

The voluntary license granted by the MPP allows Eugia to develop, manufacture, and distribute generic Nilotinib Capsules in select markets.

K Nithyananda Reddy, Vice Chairman & Managing Director of Aurobindo Pharma, expressed excitement about the sublicense agreement and highlighted that it is the first of its kind signed by the MPP for a cancer treatment in low and middle-income countries.

The addition of Nilotinib Capsules to Aurobindo’s oncology portfolio is expected to strengthen the company’s position in the generic oncology space. Aurobindo Pharma is eager to start supplying the product at the earliest to help reduce the risk of chronic myeloid leukemia (CML) in certain patients.

For feedback and suggestions, write to us at editorial@iifl.com

aurobindo pharma

Related Tags

  • Auro Pharma
  • Aurobindo Pharma
  • Buzzing Stocks
  • Drugs
  • Leukemia
  • pharmaceuticals
  • stocks in news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.